Granza Bio

Cancer-targeting attack particles derived from the immune system.

Pre-seed / SeedSan Francisco, CAFounded 2024

About

Granza Bio develops therapeutic delivery vehicles called 'attack particles' that use immune system proteins (perforin and granzyme) to selectively target and kill cancer cells with no toxicity to healthy tissue. Founded by Oxford immunology and oncology researchers, the company's proprietary delivery shells offer higher stability than lipid nanoparticles and can carry protein, DNA, and RNA cargo.

Total Funding

$8M

Key Product

Attack particle cancer therapeutic delivery platform

Geography

North America